Drawing for BYSUMLOG

USPTO serial 79301288

BYSUMLOG

Reg. 6413818Status 700Renewal
Filing date
Nov 10, 2020
Status date
Jul 13, 2021
Registration date
Jul 13, 2021
Examiner
PINO, BRIAN

Need help with BYSUMLOG?

CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Deadline: July 13th, 2027

Owner

  • NOVARTIS AG

    CH

  • NOVARTIS AG

    CH

  • NOVARTIS AG

    CH

  • Sandoz AG

    CH

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE

Prosecution history

DateCodeEvent
Jul 13, 2026REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 28, 2024CHLDCHANGE OF OWNER RECEIVED FROM IB
Dec 6, 2021FINVFINAL DECISION TRANSACTION PROCESSED BY IB
Nov 16, 2021FICSFINAL DISPOSITION NOTICE SENT TO IB
Nov 16, 2021FIMPFINAL DISPOSITION PROCESSED
Oct 13, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 13, 2021R.PRREGISTERED-PRINCIPAL REGISTER
Apr 27, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 27, 2021PUBOPUBLISHED FOR OPPOSITION
Apr 25, 2021GPNXNOTIFICATION PROCESSED BY IB
Apr 7, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 7, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 7, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 22, 2021RFNTREFUSAL PROCESSED BY IB
Mar 19, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Mar 19, 2021XAECEXAMINER'S AMENDMENT ENTERED
Mar 19, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 19, 2021GNEAEXAMINERS AMENDMENT E-MAILED
Mar 19, 2021CNEAEXAMINERS AMENDMENT -WRITTEN
Mar 4, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 4, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 4, 2021ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 4, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 4, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 4, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 2, 2021RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 2, 2021RFRRREFUSAL PROCESSED BY MPU
Mar 2, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 1, 2021CNRTNON-FINAL ACTION WRITTEN
Feb 23, 2021DOCKASSIGNED TO EXAMINER
Jan 19, 2021MAFRAPPLICATION FILING RECEIPT MAILED
Jan 14, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 13, 2021LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Dec 31, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Related guidance